Dihexa is an Angiotensin IV analog reported to promote synaptogenesis in animal models, with community use focused on cognitive enhancement and memory improvement. Typical protocols involve doses around 500 mcg/day, though reported doses range from 100 mcg to 50 mg/day, with daily administration being most common. Sleep and dreams have been occasionally reported as affected, while other potential side effects like injection-site reactions have not been a consistent theme in user reports.
Data last updated
Measured on 4 of 6 axes
Evidence shape
Dihexa currently exists as an animal-only research compound with no published human clinical trials. All available data originates from preclinical and mechanistic studies, leaving the peptide without any human-grade evidence for safety or efficacy. Because there are zero registered trials and no completed human research, the clinical profile remains entirely theoretical. This lack of human data means there is no established basis for human application, and the compound remains restricted to laboratory settings.
Human evidence
No human study rows have been captured for this peptide yet.
Lower-tier support
Published literature
The research corpus was searched; no standalone peptide-level publications were indexed beyond the trials and preclinical rows above.
Source data
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
price offers can be sorted by column
How Dihexa is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
No structured protocol details captured for this tier yet.
No structured protocol details captured for this tier yet.
Most community reports gave no schedule (typical 500 mcg); among those with a schedule, daily dosing (5 reports, typical 5 mg) was most common, followed by weekly (3), twice‑daily (1), and every‑other‑day (1).